Application of PKPD Modeling in Drug Discovery and Development

2,271
Total downloads
8,723
Total views and downloads

Articles

ORIGINAL RESEARCH

Published on 09 Oct 2024

Combining mathematical modeling, in vitro data and clinical target expression to support bispecific antibody binding affinity selection: a case example with FAP-4-1BBL

Javier Sanchez
Christina Claus
Christine McIntyre
Tamara Tanos
Axel Boehnke
Lena E. Friberg
Siv Jönsson
Nicolas Frances

doi 10.3389/fphar.2024.1472662

1,031 views

ORIGINAL RESEARCH

Published on 01 Oct 2024

PBPK-based translation from preclinical species to humans for the full-size IgG therapeutic efalizumab

Maria Franz
Ravi Kumar Jairam
Lars Kuepfer
Nina Hanke

doi 10.3389/fphar.2024.1418870

965 views

ORIGINAL RESEARCH

Published on 28 Aug 2024

Model informed dose regimen optimizing in development of leritrelvir for the treatment of mild or moderate COVID-19

Kun Wang
Haijun Li
Youyun Li
Fengyan Xu
Zhongyi Sun
Yuting Yang
Jufang Huang
Xiaoxin Chen

doi 10.3389/fphar.2024.1449583

533 views
1 citation

ORIGINAL RESEARCH

Published on 28 Aug 2024

Physiologically based pharmacokinetic models for systemic disposition of protein therapeutics in rabbits

Ravi Kumar Jairam
Maria Franz
Nina Hanke
Lars Kuepfer

doi 10.3389/fphar.2024.1427325

885 views
1 citation

ORIGINAL RESEARCH

Published on 27 Aug 2024

Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn’s disease

Kouzhu Zhu
Xiaoliang Ding
Ling Xue
Linsheng Liu
Yan Wang
Yun Li
Qinhua Xi
Xueqin Pang
Weichang Chen
Liyan Miao

doi 10.3389/fphar.2024.1430120

528 views

ORIGINAL RESEARCH

Published on 14 Mar 2024

Model-based exploration of the rationality of off-label use of cetirizine in Chinese pediatric patients: a prospective cohort study

Wei Liu
Zhiyuan Tan
Ping Yang
Zhiheng Yu
Xueting Yao
Pengxiang Zhou
Ling Liu
Wei Zhou

doi 10.3389/fphar.2024.1322788

1,038 views
1 citation

ORIGINAL RESEARCH

Published on 29 Jan 2024

Population pharmacokinetics and individualized dosing of tigecycline for critically ill patients: a prospective study with intensive sampling

Wei Su
Shuping Song
Jieqiong Liu
Haitao Yu
Binbin Feng
Yinshan Wu
Feng Guo
Zhenwei Yu

doi 10.3389/fphar.2024.1342947

1,175 views
2 citations

Share on

Frontiers in Pharmacology

Experimental Pharmacology and Drug Discovery
Gastrointestinal and Hepatic Pharmacology
Obstetric and Pediatric Pharmacology

Participating Journals

Frontiers in Pediatrics
- Obstetric and Pediatric Pharmacology
- 2.1 impact factor
- 3.6 citescore

Impact

8,723Topic views
5,311Article views
2,271Article downloads

View impact

Articles

Combining mathematical modeling, in vitro data and clinical target expression to support bispecific antibody binding affinity selection: a case example with FAP-4-1BBL

PBPK-based translation from preclinical species to humans for the full-size IgG therapeutic efalizumab

Model informed dose regimen optimizing in development of leritrelvir for the treatment of mild or moderate COVID-19

Physiologically based pharmacokinetic models for systemic disposition of protein therapeutics in rabbits

Optimising infliximab induction dosing to achieve clinical remission in Chinese patients with Crohn’s disease

Model-based exploration of the rationality of off-label use of cetirizine in Chinese pediatric patients: a prospective cohort study

Population pharmacokinetics and individualized dosing of tigecycline for critically ill patients: a prospective study with intensive sampling

Frontiers in Pharmacology

Experimental Pharmacology and Drug Discovery

Gastrointestinal and Hepatic Pharmacology

Obstetric and Pediatric Pharmacology

Participating Journals

Frontiers in Pediatrics

Obstetric and Pediatric Pharmacology